These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 16354602)

  • 1. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
    Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
    Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S; Karner I
    Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
    De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
    Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
    Khmara IM; Tolkachev IuV
    Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
    Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
    Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B; Puavilai G; Rajatanavin R
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
    Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
    Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
    Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
    López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
    Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal.
    Gao YC; Gu Q; Liu QP; Ge WL; Lu HK
    Clin Lab; 2010; 56(3-4):87-93. PubMed ID: 20476639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone mineral density in patients on long-term therapy with levothyroxine].
    Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
    Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
    Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
    Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of parathyroid status and Ca and vitamin-D supplementation on bone mass and muscle-bone relationships in 208 Belarussian children after thyroidectomy because of thyroid carcinoma.
    Schneider P; Biko J; Reiners C; Demidchik YE; Drozd VM; Capozza RF; Cointry GR; Ferretti JL
    Exp Clin Endocrinol Diabetes; 2004 Sep; 112(8):444-50. PubMed ID: 15372365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study.
    Bauer M; Fairbanks L; Berghöfer A; Hierholzer J; Bschor T; Baethge C; Rasgon N; Sasse J; Whybrow PC
    J Affect Disord; 2004 Dec; 83(2-3):183-90. PubMed ID: 15555712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation.
    Goffin E; Devogelaer JP; Lalaoui A; Depresseux G; De Naeyer P; Squifflet JP; Pirson Y; van Ypersele de Strihou C
    Transpl Int; 2002 Mar; 15(2-3):73-80. PubMed ID: 11935163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
    Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.